Agenus Inc. (NASDAQ:AGEN) traded up 4.7% during mid-day trading on Friday . The company traded as high as $6.23 and last traded at $6.22, with a volume of 1,142,314 shares traded. The stock had previously closed at $5.94.

A number of equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Agenus in a research report on Sunday, July 31st. Jefferies Group boosted their target price on Agenus from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Friday, July 29th. Maxim Group reaffirmed a “buy” rating and set a $7.00 target price on shares of Agenus in a research report on Thursday, July 28th. Finally, Zacks Investment Research raised Agenus from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $10.25.

The stock’s market cap is $540.59 million. The firm has a 50-day moving average of $4.96 and a 200 day moving average of $4.03.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Thursday, July 28th. The company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.01. The firm earned $6.59 million during the quarter, compared to the consensus estimate of $5.12 million. On average, equities research analysts anticipate that Agenus Inc. will post ($1.27) earnings per share for the current year.

Agenus Inc (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.